1 Immunological and Formulation Design Considerations for Subunit Vaccines --;2 Public Health Implications of Emerging Vaccine Technologies --;3 Preclinical Safety Assessment Considerations in Vaccine Development --;4 Regulatory Considerations in Vaccine Design --;5 Clinical Considerations in Vaccine Trials with Special Reference to Candidate HIV Vaccines --;6 Laboratory Empiricism, Clinical Design, and Social Value: The Rough Road toward Vaccine Development --;7 A Compendium of Vaccine Adjuvants and Excipients --;8 Adjuvant Properties of Aluminum and Calcium Compounds --;9 Structure and Properties of Aluminum-Containing Adjuvants --;10 MF59: Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines --;11 Development of Vaccines Based on Formulations Containing Nonionic Block Copolymers --;12 Development of an Emulsion-Based Muramyl Dipeptide Adjuvant Formulation for Vaccines --;13 Liposomal Presentation of Antigens for Human Vaccines --;14 Liposome Design and Vaccine Development --;15 Lipid Matrix-Based Vaccines for Mucosal and Systemic Immunization --;16 Polymer Microspheres for Vaccine Delivery --;17 Vehicles for Oral Immunization --;18 Design and Production of Single-Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems --;19 Nanoparticles as Adjuvants for Vaccines --;20 Water-Soluble Phosphazene Polymers for Parenteral and Mucosal Vaccine Delivery --;21 Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions --;22 Structural and Immunological Characterization of the Vaccine Adjuvant QS-21 --;23 A Novel Generation of Viral Vaccines Based on the ISCOM Matrix --;24 Vaccine Adjuvants Based on Gamma Inulin --;25 A New Approach to Vaccine Adjuvants: Immunopotentiation by Intracellular T-Helper-Like Signals Transmitted by Loxoribine --;26 Stearyl Tyrosine: An Organic Equivalent of Aluminum-Based Immunoadjuvants --;27 Cytokines as Vaccine Adjuvants: Current Status and Potential Applications --;28 Cytokines as Immunological Adjuvants --;29 Cytokine-Containing Liposomes as Adjuvants for Subunit Vaccines --;30 Haemophilus influenzae Type b Conjugate Vaccines --;31 Pneumococcal Conjugate Vaccines --;32 Lyme Vaccine Enhancement: N-Terminal Acylation of a Protein Antigen and Inclusion of a Saponin Adjuvant --;33 Vaccine Research and Development for the Prevention of Filarial Nematode Infections --;34 Retrovirus and Retrotransposon Particles as Antigen Presentation and Delivery Systems --;35 Rationale and Approaches to Constructing Preerythrocytic Malaria Vaccines --;36 The MAP System: A Flexible and Unambiguous Vaccine Design of Branched Peptides --;37 Design of Experimental Synthetic Peptide Immunogens for Prevention of HIV-1 and HTLV-I Retroviral Infections --;38 Design and Testing of Peptide-Based Cytotoxic T-Cell-Mediated Immunotherapeutics to Treat Infectious Diseases and Cancer --;39 Development of Active Specific Immunotherapeutic Agents Based on Cancer-Associated Mucins --;40 Synthetic Peptide Vaccines for Schistosomiasis --;41 Synthetic Hormone/Growth Factor Subunit Vaccine with Application to Antifertility and Cancer.
SUMMARY OR ABSTRACT
Text of Note
Vaccine Design describes scientific theories, product development strategies, and results from preclinical studies for many of the newest subunit vaccines or components designed for use in subunit vaccine formulation, such as adjuvants and vaccine delivery systems. The papers comprise the most extensive collection of vaccine technologies and products ever offered in a single volume and provides an invaluable summary of never-before-published vaccine adjuvants and excipients. This work details the use of polyphosphazines and offers a step-by-step primer for overcoming the hurdles in developing w/o/w PLGA microspheres.